{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"50.9"},{"groupId":"OG002","spread":"28","value":"44.2"},{"groupId":"OG003","spread":"41","value":"45.2"},{"groupId":"OG004","spread":"23","value":"45.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29","value":"52"},{"groupId":"OG001","spread":"35","value":"20.9"},{"groupId":"OG002","spread":"48","value":"40"},{"groupId":"OG003","spread":"57","value":"44.1"},{"groupId":"OG004","spread":"32","value":"45.2"},{"groupId":"OG005","spread":"93","value":"13.3"},{"groupId":"OG006","spread":"62","value":"22.5"},{"groupId":"OG007","spread":"54","value":"20.9"},{"groupId":"OG008","spread":"70","value":"15.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"23"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"21"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29","value":"69"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =2. Individual values = 21.2 μg/mL, 30.6 μg/mL","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"30","value":"79.8"},{"groupId":"OG003","spread":"68","value":"69.1"},{"groupId":"OG004","spread":"38","value":"61"},{"groupId":"OG005","spread":"74","value":"25.7"},{"groupId":"OG006","spread":"68","value":"33.8"},{"groupId":"OG007","spread":"102","value":"23.3"},{"groupId":"OG008","spread":"115","value":"19.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"15"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"18"}],"units":"Participants"}],"title":"Week 6"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =2. Individual values = 45.6 μg/mL, 72.5 μg/mL","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"20.6","value":"32.7"},{"groupId":"OG002","spread":"46","value":"72.8"},{"groupId":"OG003","spread":"40","value":"94.3"},{"groupId":"OG004","spread":"31","value":"78.8"},{"groupId":"OG005","spread":"60","value":"32.7"},{"groupId":"OG006","spread":"63","value":"40.1"},{"groupId":"OG007","spread":"73","value":"34.8"},{"groupId":"OG008","spread":"90","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"18"},{"groupId":"OG007","value":"11"},{"groupId":"OG008","value":"15"}],"units":"Participants"}],"title":"Week 9"},{"categories":[{"measurements":[{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =2. Individual values = 26.9 μg/mL, 38.7 μg/mL","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG002","spread":"35","value":"89.3"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =2. Individual values = 140 μg/mL, 160 μg/mL","groupId":"OG003","spread":"NA","value":"NA"},{"groupId":"OG004","spread":"38","value":"80.2"},{"groupId":"OG005","spread":"48","value":"36.8"},{"groupId":"OG006","spread":"45","value":"47.1"},{"groupId":"OG007","spread":"141","value":"34.9"},{"groupId":"OG008","spread":"89","value":"26.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"16"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"10"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"71","value":"92.4"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =2. Individual values = 147 μg/mL, 171 μg/mL","groupId":"OG003","spread":"NA","value":"NA"},{"groupId":"OG004","spread":"48","value":"87.6"},{"groupId":"OG005","spread":"45","value":"52.7"},{"groupId":"OG006","spread":"31","value":"44.4"},{"groupId":"OG007","spread":"36","value":"52.6"},{"groupId":"OG008","spread":"66","value":"37.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"11"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"9"}],"units":"Participants"}],"title":"Week 18"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"69","value":"149"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =1. Individual value = 215 μg/mL","groupId":"OG003","spread":"NA","value":"NA"},{"groupId":"OG004","spread":"34","value":"120"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"title":"Week 19"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"83","value":"116"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =1. Individual value = 178 μg/mL","groupId":"OG003","spread":"NA","value":"NA"},{"groupId":"OG004","spread":"27","value":"95.7"},{"groupId":"OG005","spread":"40","value":"43.6"},{"groupId":"OG006","spread":"29","value":"45"},{"comment":"Geometric Mean and Geometric Coefficient of Variation couldn't be calculated as n =2. Individual values = 39.5 μg/mL, 88 μg/mL","groupId":"OG007","spread":"NA","value":"NA"},{"groupId":"OG008","spread":"87","value":"42.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"26"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"23"},{"groupId":"OG007","value":"15"},{"groupId":"OG008","value":"21"}],"units":"Participants"}],"description":"PK: Cmin of Ramucirumab following administration every 3 weeks.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG000","title":"Phase 1a: Gastric-GEJ or BTC"},{"description":"Participants received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG001","title":"Phase 1 a: Gastric, NSCLC, or Urothelial Patients"},{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG002","title":"Cohort A"},{"description":"Participants with BTC cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG003","title":"Cohort A1"},{"description":"Participants with Gastric-GEJ cancer (First L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG004","title":"Cohort A2"},{"description":"Participants with Gastric-GEJ cancer (Second-Third L) received 8 mg/kg ramucirumab given IV on day 1 and 8 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG005","title":"Cohort B"},{"description":"Participants with NSCLC (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG006","title":"Cohort C"},{"description":"Participants with Urothelial cancer (Second-Fourth L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG007","title":"Cohort D"},{"description":"Participants with NSCLC cancer (First L) received 10 mg/kg ramucirumab given IV on day 1 in combination with 200 mg pembrolizumab given IV on day 1 Q3W of a 21-day cycle.","id":"OG008","title":"Cohort E"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All enrolled participants who received at least one dose of the study drug and had evaluable ramucirumab PK data. PK was assessed both in Phase 1a and 1b as per protocol analysis.","reportingStatus":"POSTED","timeFrame":"Phase 1a (Gastric-GEJ or BTC participants (pts)): Week (Wk) 1, 3, 6 and 9; Phase 1a (Gastric, NSCLC, or urothelial pts): Wk 3, 6, 9 and 12; Cohort A, A1, A2: Wk 1, 3, 6, 9, 12, 18, 19 and 24; Cohort B,C,D,E: Wk 3, 6, 9, 12, 18, 19 and 24","title":"Phase 1a and 1b: Pharmacokinetics (PK): Minimum Trough Concentration (Cmin) of Ramucirumab","type":"SECONDARY","unitOfMeasure":"micrograms/milliliter (μg/mL)"}